Fig. 1: Antibody response in HIV-positive and -negative donors recovered from COVID-19 disease.
From: Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV
a Seropositivity screen of plasma samples for antibodies against the external Spike antigen, using a recombinant Spike S11−530 subunit protein (S1), and against the full-length internal Nucleoprotein (N) antigen to confirm prior infection in HIV-negative and -positive donors. A sample absorbance >4-fold above the average background of the assay was regarded as positive. Black dots denote laboratory-confirmed cases and gray dots suspected/household contacts. b Comparison of S1 IgG and N IgG antibody titers in HIV-negative (n = 29) and c HIV-positive donors (n = 30). Red dots: hospitalized cases; black dots: mild (non-hospitalized cases); blue dots: asymptomatic cases. Plots show geometric mean. d Correlation between S1 IgG and N IgG titers in HIV-negative and -positive donors. e Neutralization titers in HIV-negative (n = 29) and -positive (n = 30) donors. Dotted lines indicate detection limit, minimum ID50 and potent levels >1000. f Proportion of HIV-negative (n = 29) and -positive (n = 30) donors with neutralizing antibodies within the given ranges. g Correlation between S1 IgG titers and neutralization titers in HIV-negative and -positive donors. The non-parametric Spearman test was used for correlation analysis. Two-tailed Mann–Whitney U test was used for group comparisons. *p < 0.05, **p < 0.01.
